Account Information

  • My Account

    Manage all your subscriptions, update your address, email preferences and change your password.

  • Help Center

    Get answers to common service questions, ask the analyst or contact our customer service department.

  • My Stock Talk Profile

    Update your stock talk name and/or picture.


This Two-Minute Market Move Could Make You Rich

This Two-Minute Market Move Could Make You Rich[Revealed] How to generate instant income from the stock market. Over and over again. At will. This technique is so powerful – and safe – we’re guaranteeing you can use it to generate $1 million (or more) in retirement cash. And we’ll even send you a $1,000 check to kickstart your journey. Go here for details.


This $1 Billion “Moonshot” Is Manna for Investors

By John Persinos on April 27, 2016

The race is on for new sources of growth in the biopharma industry, as blockbuster drugs lose patent protection and competitors join forces to cut costs. In fact, the urgency and sums involved are reminiscent of another massive project — the space race that put a man on the moon.

Progress toward a cancer cure is accelerating, and a likely victor is “immunotherapy,” one of the hottest areas of oncology research today.

Immunotherapy involves the use of the human body’s immune system components to treat a disease or disorder, typically cancer. This treatment can complement but often supplants chemotherapy and radiotherapy, both of which entail unpleasant side effects. In effect, immunotherapy pursues the age-old medical dream of allowing the body to be its own physician.

That’s why it’s become a major component of the $1 billion cancer “moonshot” announced in April by President Barrack Obama and Vice President Joe Biden. Outer space is often referred to as the “final frontier,” but you could apply the same description to the war on cancer.

The pressure for drug companies to find untapped growth opportunities is fierce, compelling companies to pursue immunology drugs for the treatment of cancer patients who are failing to respond to existing conventional therapies.

A flood of patent expirations continues to shake up the drug industry, spawning consolidation among the biggest players as they seek economies of scale. The future winners will be research-intensive companies with the strongest drug development pipe­lines and the most innovative treat­ments.

Our own medical expert Dr. Joe Duarte has been following this trend, and he’s pinpointed a pure play on immunology, a field that’s in the vanguard of cancer research. 

With leading-edge immunology treatments in development, this small company should tap long-term growth while its peers struggle with the headwinds of patent expirations and government cost-containment. In fact, we expect an important clinical announcement could come from them as soon as April 30th. To learn more, click here.

You might also enjoy…


R.I.P Bull Market—Here’s How To Protect Your Wealth

I hope you’ve enjoyed the phenomenal bull market of the past eight years…

Because it’s about to come to a screeching halt.

The Federal Reserve’s nearly decade-long spending spree has finally come to an end.

With no other options left at their disposal, the Fed has no other choice than to raise interest rates to keep inflation in check.

And that leaves you with two options…

Do nothing and suffer the agony of watching the profits you’ve accumulated over the years evaporate right before your eyes…

Or reposition your portfolio and invest in companies which prosper as inflation rises and interest rates soar.

I think the choice is clear. And I’ll show you the best new positions you can take if you click here.

Stock Talk — Post a comment Comment Guidelines

Our Stock Talk section is reserved for productive dialogue pertaining to the content and portfolio recommendations of this service. We reserve the right to remove any comments we feel do not benefit other readers. If you have a general investment comment not related to this article, please post to our Stock Talk page. If you have a personal question about your subscription or need technical help, please contact our customer service team. And if you have any success stories to share with our analysts, they’re always happy to hear them. Note that we may use your kind words in our promotional materials. Thank you.

You must be logged in to post to Stock Talk OR create an account.

Create a new Investing Daily account

  • - OR -

* Investing Daily will use any information you provide in a manner consistent with our Privacy Policy. Your email address is used for account verification and will remain private.

Stock Talk

  1. avatar
    Jim Abraham Reply April 27, 2016 at 5:04 PM EDT

    Is there one particular company we should be looking at to invest in or to follow that is spearheading this therapy